iRhythm Technologies to Present at the 41st Annual William Blair Growth Stock Conference
iRhythm Technologies (NASDAQ: IRTC) will participate in the 41st Annual William Blair Growth Stock Conference on June 2, 2021, at 11:40 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRhythm Technologies (NASDAQ: IRTC) will participate in the 41st Annual William Blair Growth Stock Conference on June 2, 2021, at 11:40 a.m. Eastern Time. The event will showcase the company's innovative approach to cardiac care, utilizing wearable biosensors and advanced data analytics for diagnosing arrhythmias.
Management's presentation can be accessed live or on-demand via the Investors section of their website. iRhythm aims to transform cardiac arrhythmia detection, potentially enhancing patient care through improved clinical management.
Details
News Market Reaction – IRTC
The recorded move for IRTC in the trading session of this news was +1.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 41st Annual William Blair Growth Stock Conference.
iRhythm’s management is scheduled to present on Wednesday, June 2 at 11:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Investor Relations Contact
Leigh Salvo
(415) 937-5404
investors@irhythmtech.com
Media Contact
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.